In the United States, USGI Medical® devices have been cleared by the FDA for approximation of soft tissue in minimally invasive gastroenterology procedures*. USGI also has a CE Mark indication for the use of its devices to treat obesity (including the POSE procedure) in those patients with a BMI of 30-40.
POSE® is an incisionless, same-day (outpatient) procedure designed to help patients control their hunger so they can eat less, lose weight and make positive lifestyle changes. The POSE procedure is available in select markets
The IOP system has been utilized in over 6,000 procedures and published in numerous medical journals throughout the world. The following is a list of select studies and their findings.
1. Espinós, J. C., et al. "Early experience with the Incisionless Operating Platform™(IOP) for the treatment of obesity." Obesity surgery 23.9 (2013): 1375-1383.
2. Miller, Karl, et al. "MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose vs. medical therapy." Obesity surgery 27.2 (2017): 310-322.
3. Lopez-Nava, G. et al The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes SOARD (2015) 11: 861-865
4. Espinós, J. C., et al. "Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure." Obesity surgery 26.5 (2016): 1081-1089.